Guides
Plain-language explainers on access routes, reimbursement and how to choose a provider. Every guide is informational self-assessment material — the eligibility check itself always happens with a clinician.
Country access guides
Psychedelic Therapy in Czechia: Every Legal Route in 2026
All four legal routes to psychedelic therapy in Czechia in 2026: reimbursed Spravato, partially covered ketamine-assisted psychotherapy, the psilocybin framework's real rollout status, and MDMA's research-only reality.
Psychedelic Therapy in France: Every Legal Route in 2026
All the legal routes to psychedelic therapy in France in 2026: hospital-only Spravato under narrow criteria, the March 2026 ketamine framework for suicidal crisis, and the honest status of psilocybin and MDMA research.
Psychedelic Therapy in Germany: Every Legal Route in 2026
All four legal routes to psychedelic therapy in Germany in 2026: GKV-reimbursed Spravato, private ketamine clinics, the two-site psilocybin compassionate use program and its renewal question, and MDMA's research-only reality.
Psychedelic Therapy in the Netherlands: Every Legal Route in 2026
All legal routes to psychedelic therapy in the Netherlands in 2026: basic-package Spravato at ENC-NL centers, hospital (es)ketamine and the oral esketamine research, psilocybin and MDMA's research-only reality, and why truffle retreats are not medical care.
Psychedelic Therapy in Poland: Every Legal Route in 2026
All legal routes to psychedelic therapy in Poland in 2026: free esketamine through NFZ drug program B.147, private ketamine clinics in Warsaw and Wrocław, and the research-only reality of psilocybin and MDMA.
Psychedelic Therapy in Spain: Every Legal Route in 2026
All legal routes to psychedelic therapy in Spain in 2026: hospital-financed Spravato and the regional-variation reality, private ketamine clinics in Barcelona, Madrid and Mallorca, and psilocybin and MDMA's research-only status.
Psychedelic Therapy in Switzerland: Every Legal Route in 2026
All four legal routes to psychedelic therapy in Switzerland in 2026: Spravato at the 52 BAG-designated centers, the limited medical use program for psilocybin, LSD and MDMA, private ketamine, and clinical trials.
Psychedelic Therapy in the UK: Every Legal Route in 2026
All the legal routes to psychedelic therapy in the UK in 2026: why NHS esketamine is closed in England but open in Scotland, private ketamine clinic costs, and the honest status of psilocybin and MDMA research.
Europe-wide guides
How to Choose a Ketamine or KAP Clinic in Europe: Licenses, Red Flags and Fair Prices
What 'licensed' actually means in each country, the warning signs that should make you walk away, realistic 2026 price ranges, and the questions to ask before booking.
Joining a Psychedelic Clinical Trial in Europe: How It Works in 2026
Phases, placebo and consent explained, why most applicants are screened out, which sponsors are recruiting across Europe in 2026, and how to search the registries.
Esketamine (Spravato): What the Evidence Shows
An evidence review of esketamine nasal spray (Spravato) for depression in Europe: the approved indication, pivotal trials (TRANSFORM, SUSTAIN, ESCAPE-TRD), the suicidal-ideation question, safety, and how EU access works.
For Clinicians: Referring a Patient to Psychedelic Medicine in Europe
An informational summary for GPs and psychiatrists: when treatment-resistant depression opens the esketamine route, what documentation receiving centers need, country-specific referral mechanics, trials as a referral option, and how this directory's registry verification works.
How to Help a Loved One Consider Psychedelic Therapy
A practical guide for family members and partners: how to recognize when standard depression treatment is not working, how to talk about psychedelic therapy without pushing, the documents that genuinely help, and what to do in a crisis.
Insurance & Reimbursement for Psychedelic Medicine in Europe: The 2026 Country Map
Which European countries reimburse esketamine (Spravato), ketamine and psychedelic therapy in 2026, under what criteria, who decides — and the exceptional pathways most patients never hear about.
Ketamine for Depression: What the Evidence Shows
An evidence review of racemic ketamine for depression in Europe: the IV infusion evidence base, single vs repeated infusions, meta-analyses, ketamine-assisted psychotherapy, off-label reality, and Norway's public-funding milestone.
MDMA-Assisted Therapy: What the Evidence Shows
An honest, tiered look at the MDMA-assisted therapy evidence base for PTSD in 2026: the two Phase 3 trials, the FDA's 2024 rejection and what it means for Europe, safety, and how access actually works.
Psilocybin Therapy: What the Evidence Shows
An honest, tiered look at the psilocybin evidence base in 2026: the Phase 3 depression results, what is still early, safety and exclusion criteria, and how legal access actually works in Europe.
Where in Europe Can You Actually Get Psychedelic Therapy in 2026?
The 2026 comparison: which European countries offer legal esketamine, ketamine, psilocybin and MDMA therapy, where public systems pay, where only private clinics operate — and what travelling for treatment really involves.